852062-08-9

Usage

Uses

Used in Medicinal Chemistry:
4-Chloro-7-Methoxyquinoline-3-carboxylic acid is used as a building block for the synthesis of pharmaceutical drugs. Its structural features make it suitable for the development of drug candidates targeting specific biological pathways, contributing to the discovery of new therapeutic agents.
Used in Drug Development:
In the pharmaceutical industry, 4-Chloro-7-Methoxyquinoline-3-carboxylic acid is used as a key component in the development of drug candidates. Its unique structure allows for the design of molecules that can interact with specific biological targets, potentially leading to the creation of novel treatments for various diseases.
Used as a Fluorescent Probe:
4-Chloro-7-Methoxyquinoline-3-carboxylic acid is used as a fluorescent probe in research applications. Its fluorescent properties enable it to be used for tracking and visualizing specific biological processes or interactions, aiding in the study of cellular and molecular mechanisms.
Used as a Chemical Intermediate:
In the chemical industry, 4-Chloro-7-Methoxyquinoline-3-carboxylic acid serves as a valuable intermediate in the synthesis of various compounds. Its reactivity and functional groups make it a versatile building block for the production of a wide range of chemical products.

Upstream product

• 77156-85-5 Ethyl 4-chloro-7-methoxyquinoline-3-carboxylate 

Relevant academic research and scientific papers

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.